BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 28244407)

  • 1. Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer.
    Shaikh T; Li T; Handorf EA; Johnson ME; Wang LS; Hallman MA; Greenberg RE; Price RA; Uzzo RG; Ma C; Chen D; Geynisman DM; Pollack A; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):722-731. PubMed ID: 28244407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial.
    Hamstra DA; Mariados N; Sylvester J; Shah D; Karsh L; Hudes R; Beyer D; Kurtzman S; Bogart J; Hsi RA; Kos M; Ellis R; Logsdon M; Zimberg S; Forsythe K; Zhang H; Soffen E; Francke P; Mantz C; Rossi P; DeWeese T; Daignault-Newton S; Fischer-Valuck BW; Chundury A; Gay H; Bosch W; Michalski J
    Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):976-985. PubMed ID: 28209443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial.
    Hoffman KE; Voong KR; Pugh TJ; Skinner H; Levy LB; Takiar V; Choi S; Du W; Frank SJ; Johnson J; Kanke J; Kudchadker RJ; Lee AK; Mahmood U; McGuire SE; Kuban DA
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1074-84. PubMed ID: 24661661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer.
    Hoffman KE; Voong KR; Levy LB; Allen PK; Choi S; Schlembach PJ; Lee AK; McGuire SE; Nguyen Q; Pugh TJ; Frank SJ; Kudchadker RJ; Du W; Kuban DA
    J Clin Oncol; 2018 Oct; 36(29):2943-2949. PubMed ID: 30106637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial.
    Hoffman KE; Skinner H; Pugh TJ; Voong KR; Levy LB; Choi S; Frank SJ; Lee AK; Mahmood U; McGuire SE; Schlembach PJ; Du W; Johnson J; Kudchadker RJ; Kuban DA
    Am J Clin Oncol; 2018 Jun; 41(6):558-567. PubMed ID: 27635624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
    Wilkins A; Mossop H; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Patterson H; Birtle A; Staffurth J; Malik Z; Panades M; Eswar C; Graham J; Russell M; Kirkbride P; O'Sullivan JM; Gao A; Cruickshank C; Griffin C; Dearnaley D; Hall E
    Lancet Oncol; 2015 Dec; 16(16):1605-16. PubMed ID: 26522334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
    Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
    Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Phase II Trial of Once-weekly Hypofractionated Radiation Therapy for Low-risk Adenocarcinoma of the Prostate: Late Toxicities and Outcomes.
    Zimmermann M; Taussky D; Menkarios C; Vigneault É; Beauchemin MC; Bahary JP; Martin AA; Diaz de Bedoya LV; Lambert C
    Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):386-92. PubMed ID: 26782838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal analysis of quality of life in patients receiving conformal radiation therapy for prostate cancer.
    Geinitz H; Thamm R; Scholz C; Heinrich C; Prause N; Kerndl S; Keller M; Busch R; Molls M; Zimmermann FB
    Strahlenther Onkol; 2010 Jan; 186(1):46-52. PubMed ID: 20082188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial.
    Viani GA; Viana BS; Martin JE; Rossi BT; Zuliani G; Stefano EJ
    Cancer; 2016 Jul; 122(13):2004-11. PubMed ID: 27028170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
    Shahid N; Loblaw A; Chung HT; Cheung P; Szumacher E; Danjoux C; Sankreacha R; Zhang L; Deabreu A; Mamedov A; Morton G
    Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):412-420. PubMed ID: 28190638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy.
    Akthar AS; Liao C; Eggener SE; Liauw SL
    Eur Urol; 2019 Nov; 76(5):686-692. PubMed ID: 31113644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
    Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
    Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial.
    Bruner DW; Pugh SL; Lee WR; Hall WA; Dignam JJ; Low D; Swanson GP; Shah AB; Malone S; Michalski JM; Dayes IS; Seaward SA; Nguyen PL; Pisansky TM; Chen Y; Sandler HM; Movsas B
    JAMA Oncol; 2019 May; 5(5):664-670. PubMed ID: 30763425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life impact of treatments for localized prostate cancer: cohort study with a 5 year follow-up.
    Ferrer M; Guedea F; Suárez JF; de Paula B; Macías V; Mariño A; Hervás A; Herruzo I; Ortiz MJ; Ponce de León J; Sancho G; Boladeras A; Ayala A; Craven-Bratle J; Ávila M; Cunillera O; Pardo Y; Alonso J; Aguiló F;
    Radiother Oncol; 2013 Aug; 108(2):306-13. PubMed ID: 23849168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of Life after post-prostatectomy intensity modulated radiation therapy to the prostate bed with or without the use of gold fiducial markers for image guidance or higher total radiotherapy doses.
    Abuodeh YA; Naghavi AO; Juan TH; Ma Z; Wilder RB
    Int Braz J Urol; 2017; 43(4):628-637. PubMed ID: 28379660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Ultrahypofractionated Whole Pelvis Radiation Therapy (WPRT) as Well Tolerated as Conventionally Fractionated WPRT in Patients With Prostate Cancer? Early Results From the HOPE Trial.
    Mendez LC; Crook J; Martell K; Schaly B; Hoover DA; Dhar A; Velker V; Ahmad B; Lock M; Halperin R; Warner A; Bauman GS; D'Souza DP
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):803-812. PubMed ID: 38072323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients.
    Norkus D; Karklelyte A; Engels B; Versmessen H; Griskevicius R; De Ridder M; Storme G; Aleknavicius E; Janulionis E; Valuckas KP
    Radiat Oncol; 2013 Sep; 8():206. PubMed ID: 24007322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial.
    Voong KR; Lal LS; Kuban DA; Pugh TJ; Swint JM; Godby J; Choi S; Lee AK; Schlembach PJ; Frank SJ; McGuire SE; Hoffman KE
    Adv Radiat Oncol; 2017; 2(3):249-258. PubMed ID: 29114589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016).
    Staffurth JN; Haviland JS; Wilkins A; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Birtle A; Malik Z; Panades M; Eswar C; Graham J; Russell M; Ferguson C; O'Sullivan JM; Cruickshank CA; Dearnaley D; Hall E;
    Eur Urol Oncol; 2021 Dec; 4(6):980-992. PubMed ID: 34489210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.